The Hood Certificate Expired Fourteen Months Ago
You are pharmacist-in-charge of an independent pharmacy that prepares sterile compounded preparations for two home infusion patients and a local hospice. A self-audit reveals: the primary engineering control in the IV room was last certified 14 months ago; there are no written cleaning procedures and no environmental monitoring records; the technician who prepared yesterday's batch of 12 prefilled ceftriaxone syringes has no documented sterile compounding training; and the pharmacy has been assigning a 30-day beyond-use date to syringes stored at room temperature. Nothing has been recalled. The hospice expects its delivery this afternoon.
1. May the pharmacy release today's batch and continue sterile compounding?
Read the worked answer
No. Sterile compounding is conditional, not a standing privilege.
Alabama Board rules adopt the USP <797> standards for sterile compounding. On these facts the pharmacy is out of compliance on at least four independent requirements: equipment certification at the required interval, documented cleaning and disinfection, environmental monitoring, and documented personnel training and competency.
Actions:
- Quarantine the 12 syringes; do not release them.
- Suspend sterile compounding until the hood is certified, training and competency are documented, SOPs exist, and environmental monitoring is in place.
- Notify the hospice now so it can source product elsewhere; patient care continuity is part of the obligation.
- Assess the already-dispensed syringes made during the lapsed period for sterility risk and notify prescribers and patients as appropriate.
- Document each step and the corrective action timeline.
A pharmacist-in-charge who "waits until next month" to recertify has authorized noncompliant compounding in the interim.
2. What is wrong with the 30-day room-temperature beyond-use dating, and what should replace it?
Read the worked answer
A BUD cannot be chosen for convenience. It must be assigned from the <797> framework using the preparation's risk category, the storage conditions, and validated stability information, and it cannot exceed the assigned limit for that category and storage temperature.
Apply it: a 30-day room-temperature BUD for a syringe preparation is not supportable under that framework; room-temperature limits are far shorter. A longer dating period would require a qualifying lower-risk classification, refrigerated or frozen storage as applicable, and documented stability.
Corrective path:
- Reassign BUDs using the current standard and document the basis for each.
- Recall or replace any product whose remaining labeled BUD exceeds what the pharmacy can now justify.
- Use only in-date product; never relabel to extend dating.
- Add a second-person check on BUD assignment before release.
Also note 503A limits: ceftriaxone is commercially available, so compounding it requires a patient-specific prescription and a documented clinical reason the commercial product will not serve (e.g., concentration or preservative difference). Do not compound in anticipation of demand.